期刊文献+

喹硫平联用碳酸锂治疗双相障碍抑郁相的对照研究 被引量:4

A control study of quetiapine combined with lithium in the treatment of bipolar depression
下载PDF
导出
摘要 目的通过喹硫平和氟西汀分别联用碳酸锂对双相型障碍抑郁相的对照研究,评价喹硫平的8周效果及安全性。方法两组入组32例和31例,年龄(30.6±10.2)岁和(31.6±11.2)岁,完成8周治疗30例和28例,脱落率为6.3%和9.7%。两组碳酸锂剂量(1.1±0.3)g/d和(1.1±0.3)g/d,喹硫平、氟西汀剂量分别为(320.0±89.6)mg/d和(27.2±11.2)mg/d。结果两组8周有效率(减分率≥50%者)为70.0%和78.6%,经Ridit分析两组差异无统计学意义,P>0.05。治疗2、4、8周与治疗前HAMD总分及因子分经配对比较,两组下降差异有统计学意义,P<0.01。在同期因子减分比较中,喹硫平组的焦虑躯体化和迟缓因子分别在2、4、8周时低于氟西汀组,睡眠障碍因子却在4、8周时大于氟西汀组,差异有统计学意义,P<0.05~0.01。两组不良反应按SS集分析中,喹硫平组更多具有困倦嗜睡、体重增加;氟西汀组多反映在失眠多梦、口干、出汗;两组差异有统计学意义,P<0.05~0.01。结论两组在碳酸锂剂量相同的情况下,8周疗效相当,不良反应基本相似,但喹硫平组未见转躁患者。 Objective To explore the curative effect and safety of quetiapine combined with lithium in the treatment of bipolar depression.Methods There were 32 patients aged(30.6 ± 10.2) years in research group receiving quetiapine plus lithium,dose of(320.0 ± 89.6) mg / day and(1.1 ± 0.3) g / day.And 31 patients aged(31.6 ± 11.2) years in research group receiving fluxetine plus lithium,dose of(27.2 ± 11.2) mg / day and(1.1 ± 0.3) g / day.After 8 weeks of treatment,there were 30 cases and 28 cases remained,the loss rates were 6.3% and 9.7%.Results The efficiency(reduced rate ≥50%) of the two groups was 70.0% and 78.6%,there was no significant difference(p 0.05).Compared with the HAMD total score and factor scores before treatment and at 2,4,8 weeks,there were both significant difference decreased(P0.01) in the two groups.Sub factor in the same period by comparison,the anxiety and retardation factors in quetiapine group were lower than in fluoxetine group at 2,4,8week.The sleep disturbance factor in quetiapine group was greater than in fluoxetine group at 4,8weeks.There was significant and very significant difference(P0.05~0.01).According to the analysis of SS,there were more sleepy lethargy,weight gain in quetiapine group,and more insomnia,dry mouth,sweating in fluoxetine group,there were significant or very significant differences(P0.05~0.01) between the two groups.Conclusion In the case of the same dose of lithium,two groups were effective,with similar side effects,but there was no case induced to mania in quetiapine group.
出处 《四川医学》 CAS 2012年第4期668-671,共4页 Sichuan Medical Journal
关键词 喹硫平 碳酸锂 联合治疗 双相型障碍 抑郁相 quetiapine lithium combine bipolar disorder depression
  • 相关文献

参考文献5

二级参考文献26

  • 1胡纪泽,吴东辉,刘仁刚,丁树明,冯征,董松玉,曹长安,胡赤怡,林雄标,舒明跃,吴怀安,方莉,唐卓如,包刚.抑郁障碍共患其他精神障碍的研究[J].中华精神科杂志,2005,38(2):98-100. 被引量:38
  • 2于君,郝增平,王培磊.万拉法新联合阿普唑仑治疗伴焦虑症状抑郁症对照研究[J].临床心身疾病杂志,2006,12(1):21-22. 被引量:10
  • 3Goodwin GM, Malhi GS. What is a mood stabilizer? Psychological Medicine, 2007; 37: 609-614.
  • 4Bauer MS, Mitchner L. What is a "mood stabilizer"?. An evidence-based response. Am J Psychiatry, 2004; 161 : 3-18.
  • 5岡本泰昌,日域広昭.バルブロ酸·カルバマゼビンにょる雙極性障害治療.臨床精神醫學,2008;37(7):881-888.
  • 6堤祐一郎.非定型抗精神病藥ほ気分安定藥になりラるか?-気分安定の臨床の現狀とその問題點につぃて,歷史的經緯と今后の展望を含め,幅広ぃ視點からの解說-.臨床精神医学,2008;37(7):919-930.
  • 7Tohen M, Baker RW, Ahshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry, 2002; 159: 1011-1017.
  • 8Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 2003; 60: 1079-1088.
  • 9Jones M, Huizar K, Quetiapine monotherapy for acute mania associated with bipolar disorder ( STAMP 1 and STAMP 2). Bipolar Disord. 2003 ; 5 ( suppl 1 ) : 57.
  • 10Sachs G, Chengappa K, Suppes T, et al. Quetiapine with lithium or divaproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled. Bipolar Disord, 2004; 6: 213-223.

共引文献135

同被引文献53

  • 1吉中孚.第2代抗精神病药治疗双相障碍的临床疗效评价[J].中国医院用药评价与分析,2007,7(3):180-183. 被引量:3
  • 2刘珺,管娟,王铭,等.喹硫平单药治疗双相障碍躁狂发作疗效研究[J].中华临床医师杂志(电子版),2013(23):10717-10720.
  • 3Fisher DS,Handley SA,Taylor D,et al.Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-M S/M S[J].Biomedical Chromatography,2012,26(9):1125-1132.
  • 4Li X,Cameron MD.Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis[J].Chemical Research in Toxicology,2012,25(5):1004-1011.
  • 5Pandhare A,Hamouda AK,Staggs B,et al.Bupropion binds to tw o sites in the torpedo nicotinic acetylcholine receptor transmembrane domain:a photoaffinity labeling study w ith the bupropion analog[J].Biochemistry,2012,51(12):2425-2435.
  • 6Bassett DL. Risk assessment and management in bipolar disorders [ J ]. Med J Aust, 2010, 193 (4 Suppl) : S21 -23.
  • 7Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 [ J]. Bipolar Disord, 2013, 15 (1): 1-44.
  • 8Niufan G, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a doubld - blind, randomized, controlled trial [ J ]. J Affect Disord, 2008, 105 ( 1/2/3 ) : 101 - 108.
  • 9Goodwin G, Flei~ehhaeker W, Arango C, et al. Advantages and dis- advantages of combination treatment with antipsyehoties ECNP Consensus Meeting, March 2008, Nice [ J]. Eur Neumpsychopharmacol, 2009, 19 (7) : 520 -532.
  • 10Bowden CL, Myers JE, Grossman F, et al. Rispefidone in combina- tion with mood stabilizers: a 10 -week continuation phase study in bi-polar I disorder [J]. J Cllo Psychiatry, 2004, 65 (5) : 707 -714.

引证文献4

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部